BUSINESS

Next Astellas CEO Says Weathering Xtandi Cliff Is His Biggest Mission

By Takashi Ebisawa February 7, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

With the loss of exclusivity for Xtandi (enzalutamide) looming later in the decade, Naoki Okamura, the incoming chief of Astellas Pharma, says that his biggest assignment is to overcome its patent cliff by speeding up the work on newer modalities…

To read the full story

Astellas EVP Okamura to Become CEO in April
February 6, 2023

BUSINESS

RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
Obesity Market Projected at 46.6 Billion Yen by 2040 as GLP-1s Fuel Growth: Fuji Keizai
December 15, 2025
Roche Diagnostics Taps Ex-Medtronic Japan VP Maeda as New CEO
December 15, 2025
Chugai to Launch US Partnering Office in January 2026
December 15, 2025
Scrap “Spillover,” “Special” Rules If G1 Rule Is Applied Early: Chugai CEO
December 15, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…